Program

Full Program

Posters


Friday, October 2, 2020
08:00 - 08:25 CDT	Welcome & Opening Keynote Chairs: David R. Gandara, USA & Christian Rolfo, USA & Maria Arcila, USA Chair’s Welcome Personalizing Lung Cancer Treatment – Pasi Janne, USA Live Q&A
08:30 – 09:40 CDT	Opening Keynote & Understanding the Basics for Liquid Biopsy (ctDNA) Chair: Lynette Sholl, USA Preanalytics in ctDNA Handling: A Crucial Point – Umberto Malapelle, Italy Technologies Update from Single to Multiple Determinations – Ignacio Wistuba, USA Advantages and Disadvantages to In-house vs Outsourcing Analyses with Liquid Biopsy – David R. Gandara, USA & Maria Arcila, USA Live Q&A with all Presenters Moderated by Lynette Sholl, USA
09:40 – 09:55 CDT	Break
09:55 – 11:25 CDT	Clinical Application of Liquid Biopsy I (ctDNA) Chair: Natasha Leighl, Canada Integrating Liquid Biopsy into Clinical Practice: Which Patients with NSCLC? – Natasha Leighl, Canada Presentation of IASLC Consensus Statement Results – Christian Rolfo, USA Clinical Cases in Molecular Tumor Board Debate: Case Advanced NSCLC - Adenocardinoma – Natasha Leighl, Canada; Lecia Sequist, USA; Tony Mok, Hong Kong Live Q&A moderated by Natasha Leighl, Canada Cross Fire Session: Liquid versus Tissue Biopsy… or Complementary – Maria Arcila, USA & Marina Garassino, Italy Quantitation of Variant Allele Frequency and Variants in the Decision-Making Process: Molecular Biology Perspective and Pathology Perspective – Phil Mack, USA & Lynette Sholl, USA Live Q&A Moderated by Natasha Leighl, Canada
11:25 – 11:40 CDT	Break
11:40 – 12:20 CDT	Prime Time for Blood First Chair: Maria Arcila, USA No, Tissue is the Issue – Fred R. Hirsch, USA Yes, It Is Prime Time – Rafal Dziadziuszko, Poland Live Q&A Moderated by Maria Arcila, USA
12:20 – 13:30 CDT	Liquid Biopsy and Checkpoint Immunotherapy (CPI) Chairs: Benjamin Besse, France Tumor Mutational Burden (TMB): Moving from Tumor Tissue to Blood – Phil Mack, USA Analytical and Clinical Validation of a Blood TMB Assay – David R. Gandara, USA Other Potential Predictive Biomarkers in ctDNA for CPI – Maximilian Diehn, USA Live Q&A Moderated by Benjamin Besse, France Closing Remarks of the Day – Giorgio Scagliotti, Italy
13:30 - 14:30 CDT	Poster Viewing Time with Presenters Being Online
Saturday, October 3, 2020
08:00 – 08:55 CDT	What Are the Real Challenges for a Worldwide Application? Chairs: Kazuto Nishio, Japan & Harpreet Singh, USA & Christian Rolfo, USA Liquid Biopsy Regulations from FDA Perspective – Harpreet Singh, USA Panel Discussion: What Are the Real Challenges for a Worldwide Application? Laureen Leiman, USA Nikki Martin, USA Michelle Turner, USA Harpreet Singh, USA Chandra Belani, USA Live Q&A Moderated by Christian Rolfo, USA
08:55 – 09:35 CDT	Understanding Other Members of the Liquid Biopsy Family Chair: Harpreet Singh, USA Liquid Biopsy and Clonal Evolution of Lung Cancer - Collin Blakely, USA Cancer Interception: A New Opportunity for Liquid Biopsy – Lecia Sequist, USA Live Q&A Moderated by Harpreet Singh, USA
09:35 – 09:50 CDT	Break
09:50 – 11:40 CDT	Increasing Roles for Liquid Biopsy: Moving from Research to Clinical Application Chairs: Chandra Belani, USA & Charu Aggarwal, USA Detection of Early Stage Disease: Complementary or Replacement for CT Screening – Nir Peled, Israel Early Detection of Recurrence after Surgery: TRACERx, Minimal Residual Disease and Adjuvant Trials – Chris Abbosh, UK Liquid Biopsy for Detection of Minimal Residual Disease – Tetsuya Mitsudomi, Japan Live Q&A with all Presenters Moderated by Charu Aggarwal, USA Liquid Biopsy for Tumor Monitoring – Natasha Leighl, Canada Liquid Biopsy for Determination of Mechanisms of Resistance – Charu Aggarwal, USA ctRNA: Exploring Other Opportunities in Liquid Biopsy – Luis Raez, USA Live Q&A with all Presenters Moderated by Chandra Belani, USA
11:40 – 12:40 CDT	Symposium by AstraZeneca: Liquid Biopsy Testing Strategies for Patients with Metastatic NSCLC: A Case-Based Program
12:40 – 13:20 CDT	Liquid Biopsy in Clinical Trials Chair: Christian Rolfo, USA Integrating Liquid Biopsy in Lung Cancer Clinical Trial Design – Benjamin Besse, France Update of the Ongoing Trials in Liquid Biopsy – Rafal Dziadziuszko, Poland Live Q&A Moderated by Christian Rolfo, USA
13:20 – 14:00 CDT	Molecular Tumor Board Discussion Chair: Shirish Gadgeel, USA Panel Discussion: Lynette Sholl, USA Umberto Malapelle, Italy Marina Garassino, Italy Charu Aggarwal, USA Live Q&A Moderated by Shirish Gadgeel, USA
14:00 – 14:15 CDT	Closing Session Closing Remarks: Christian Rolfo, USA Maria Arcila, USA David R. Gandara, USA

Featured Poster: Potential of Plasma Circulating Tumor DNA as a Monitoring Tool in Patients with Advanced EGFR-mutated NSCLC - Vichitra Behel, India
Featured Poster: Treatment Induced Tumor Lysis to Enhance Sensitivity of ctDNA Analysis and Its Prognostic Value: A First-in-human Pilot Study - Daniel Breadner, Canada
Featured Poster: Circulating Tumor Cells and Tissue AXL as the New Prognostic Biomarkers in Resected Non-small Cell Lung Cancer Patients. - Diego De Miguel Perez, USA
Featured Poster: Extracellular Vesicle miRNAs and Autophagy-activated CTCs Are Predictive and Prognostic Biomarkers in Advanced Non-small Cell Lung Cancer Patients. - Diego De Miguel Perez, USA
Featured Poster: Identification of New Biomarkers in Non-Small Cell Lung Cancer (NSCLC) by Analyzing Exosomes Cargo - Elena Duréndez-Sáez, Spain
Featured Poster: Longitudinal Disease Monitoring of Circulating Tumor DNA in EGFR T790M Mutation-positive Non–small-cell Lung Cancer Patients Receiving Treatment with Osimertinib (WJOG8815L) - Asuka Okada, Japan
Featured Poster: Pilot Study of a Novel Liquid Biopsy Test to Discriminate Benign vs Malignant Processes in Subjects with Indeterminate Pulmonary Nodules - Paul Pagano, USA
Featured Poster: Clinical Utility of Circulating Genetically Abnormal Cells in Differential Diagnosis of Benign from Malignant Pulmonary Nodules Sized Between 5-10mm - Jiayuan Sun, China
Mutational Landscape and Tumor Mutation Burden of Indian NSCLC Patients - Sewanti Limaye, India
Detection of Resistant T790M Mutation of EGFR from Pleural Effusion and Other Body Fluids in Lung Adenocarcinoma Patients - Anuradha Anuradha, India
Molecular Characterization of Lung Cancer Brain and Leptomeningeal Metastases via Clinical Next Generation Sequencing of Cell-Free DNA From Cerebrospinal Fluid - Tejus A Bale, USA
Shifting Paradigms in the Detection of Primary EGFR Mutations - Ullas Batra, India
Utility of Liquid Biopsy in Diagnosis and Treatment Response in EGFR Mutant NSCLC Patients with Leptomeningeal Involvement - David Berz, USA
Analysis of Plasma-derived Extracellular Vesicle (EV) Cargo Using the nCounter Nanostring Platform - Jillian Bracht, Spain
A Pilot of Diagnostic Circulating Tumour (ct) DNA Next Generation Sequencing (NGS) Assessment in Patients with Suspected Advanced Lung Cancer During the COVID-19 Pandemic - Wanyuan Cui, UK
Clinical Utility of ctDNA Next Generation Sequencing (NGS) for Target Identification in Diagnostic and Acquired Resistance Settings in Metastatic NSCLC – A Single Centre Experience - Wanda Cui, UK
Characterization of Peripheral T-Cell Receptor β Chain Repertoire in Advanced Non-small Cell Lung Cancer Patients Treated with Pembrolizumab - Ning Dong, Spain
Predictive and Prognostic Role of Soluble Biomarkers in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Anti-PD1/PDL1 Immunotherapy - Susana Torres, Spain
The Prognostic Impact of Blood Tumor Mutational Burden (bTMB) in the First-line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-analysis of Randomized Trials - Valerio Gristina, Italy
Molecular Features of Gene Alteration Profiles in Circulating Cell-free DNA of Advanced Non-small Cell Lung Cancer Patients - Hideharu Kimura, Japan
The VALUE of Routine Liquid Biopsy for NSCLC Patients in a Public Healthcare System - Natasha Leighl, Canada
Non-invasive Diagnostic Triaging of Suspected Lung Cancers Based on Immunocytochemistry Profiling of Circulating Tumor Cells - Dadasaheb Akolkar, India
Circulating Free DNA Expression in Lung Cancer Surgical Patients - Joana Espiga de Macedo, Portugal
The role of liquid biopsy in Non-Small Cell Lung Cancer basal setting patients: focus on KRAS mutations. - Umberto Malapelle, Italy
The Role of Liquid Biopsy in Non-Small Cell Lung Cancer Basal Setting Patients: Focus on EGFR Mutations. - Umberto Malapelle, Italy
The Role of Liquid Biopsy in Lung Cancer: Focus on Prevention. - Umberto Malapelle, Italy
Lung Cancer Testing Using Sputum: A Non-Invasive Liquid Biopsy - Michael Meyer, USA
NGS-based Liquid Biopsy as a Non-invasive Tool to Identify Targetable Alterations in Non-Small-Cell Lung Cancer (NSCLC) Patients - Andrea Moreno, Spain
Use of an Artificial Intelligence-derived Algorithm for Accurate FISH Probe Detection in a Liquid Biopsy Test for Lung Cancer - Paul Pagano, USA
Circulating Tumor Cell as a Predictive Marker for Immunotherapy in Advanced Non-Small Cell Lung Cancer - Cheol-kyu Park, Korea
Real-World Data: Importance of Monitoring Blood-Based KRAS Mutations and Immune Status in Patients with Advanced NSCLC - Edgardo Santos, USA
The Turnaround Time Impact of Liquid Biopsy in Comparison with Tissue Biopsy in Advance NSCLC - Or Sehayek, Israel
Gene Mutation Profiles in Liquid Biopsies Upon Development of Resistance to Afatinib - Nanao Terada, USA
Clinical Utility of Personalised Somatic Genomic Rearrangement Biomarkers after Surgical Resection of Non-small Cell Lung Cancer - Boris Wong, Australia
Ultra-rapid Detection of Circulating EGFR Mutations from Plasma Under 3 Hours and Without Prior Cell-free DNA Extraction - Soo-Ryum Yang, USA
A ‘Plasma-first’ Molecular Profiling Approach Complements Actionable Mutation Detection in Suspected Lung Cancer Patients - Jamie Mong, Singapore

Stay Connected